29th Jan 2016 08:09
LONDON (Alliance News) - Gene and cell therapy company Oxford Biomedica PLC on Friday said it has started work on a second Chimeric Antigen Receptor T cell programme under its deal with Swiss pharmaceuticals giant Novartis AG.
Oxford Biomedia will handle process development and manufacturing of the lentiviral vector used in the new programme, under an agreement struck with Novartis in October 2014.
No financial details were disclosed.
"We are excited to be providing Novartis with the licence, process development and manufacturing that they require for CTL019 and now for a second CART programme," said Oxford Biomedica Chief Executive John Dawson.
Shares in Vedanta were up 7.9% to 7.4755 pence early Friday, one of the best performers in the FTSE All-Share.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica